Antiphospholipid antibodies testing and pregnancy outcomes in recurrent implantation failure women, is it necessary?

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20231003007

Enrollment

250

Registered

2023-10-03

Start date

2022-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent implantation failure women Recurrent implantation failure Antiphospholipid antibodies ICSI

Interventions

Women who had aPL testing,Women who had no aPL testing

Prevention,Prevention

aPL testing,no aPL testing

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Women with recurrent implantation failure (more than 2 times)

Exclusion criteria

Exclusion criteria: Women with a history of thrombosis Women diagnosed antiphospholipid syndrome Women with uncorrected anatomical abnormalities Women with uncontrolled autoimmune diseases Women with uncontrolled endocrine disorders Women who have an abnormal karyotype Women who treated with anticaogulant

Design outcomes

Primary

Measure	Time frame
Pregnancy outcomes 5 years Percentage	—

Secondary

Measure	Time frame
Factor associated with pregnancy outcomes 5 years factors,Incidence of aPL positive None Percentage	—

Countries

Thailand

Contacts

Public ContactTarinee Rungjirajittranon

Faculty of Medicine Siriraj Hospital, Mahidol University

taitharee@gmail.com0855551423

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026